ANDA Approvals Continue To Accelerate As FDA Breaks Monthly Record
This article was originally published in The Pink Sheet Daily
Agency well positioned for user fee negotiations after third strong month in a row.
You may also be interested in...
A proposed pilot program would offer for “split submission and review” of some application sections in other disease areas. Discussions also touch on concept of a CDER-CBER RWE committee.
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.